MolecuLight All-in-One Oxygenation Clinical Utility

A Prospective, Clinical Evaluation of the MolecuLightDX+ With OxySight Module to Observe the Clinical Utility of Tissue Oxygenation, Bacterial Fluorescence and Thermal Signatures

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07646938

Enrollment

Registered

2026-06-15

Start date

2026-03-25

Completion date

2026-03-27

Last updated

2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wounds

Brief summary

This is a prospective, clinical evaluation of the MolecuLightDX+ with OxySight Module in wound care.

Interventions

DEVICEMolecuLightDX+ with OxySight Module

MolecuLightDX+ with OxySight Module is an imaging device intended to acquire fluorescence, oxygenation, thermal, and measurement images of wounds.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Male or female patients presenting with a wound * A wound is \> 1 cm2 in area * 18+ years old * Willing to consent

Exclusion criteria

* Contraindication to debridement * Undergoing radio- or chemotherapy * Wound located in a difficult to image location * Any condition deemed by the investigator to interfere with safety or data validity * Inability or unwillingness to consent

Design outcomes

Primary

Measure	Time frame	Description
Tissue oxygenation informing fluorescence-guided debridement	up to 1 month	Evaluate the feasibility of using tissue oxygenation (StO2) to further inform fluorescence-guided debridement.
Tissue oxygenation changes before and after debridement	up to 1 month	Observe and quantify changes in tissue oxygenation (StO2) from before to immediately after fluorescence-guided debridement.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026